| Assessment Status |
Rapid Review Complete |
| HTA ID |
26024 |
| Drug |
Zilucoplan |
| Brand |
Zilbrysq® |
| Indication |
Zilucoplan (Zilbrysq®) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are all anti-acetylcholine receptor (AChR) antibody positive. |
| Rapid review commissioned |
13/05/2026 |
| Rapid review completed |
27/05/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of zilucoplan compared with the current standard of care. |
